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Abstract 
Background: An outbreak of leishmaniasis caused by Leishmania infantum was declared in the southwest of the 
Madrid region (Spain) in June 2009. This provided a unique opportunity to compare the management of visceral 
leishmaniasis (VL) in immunocompetent adults (IC‑VL), patients with HIV (HIV‑VL) and patients receiving immunosup‑
pressants (IS‑VL).
Methods: A cohort of adults with VL, all admitted to the Hospital Universitario de Fuenlabrada between June 2009 
and June 2018, were monitored in this observational study, recording their personal, epidemiological, analytical, diag‑
nostic, treatment and outcome variables.
Results: The study population was made up of 111 patients with VL (10% HIV‑VL, 14% IS‑VL, 76% IC‑VL). Seventy‑one 
percent of the patients were male; the mean age was 45 years (55 years for the IS‑VL patients, P = 0.017). Fifty‑four per‑
cent of the IC‑VL patients were of sub‑Saharan origin (P = 0.001). Fever was experienced by 98% of the IC‑VL patients 
vs 73% of the LV‑HIV patients (P = 0.003). Plasma ferritin was > 1000 ng/ml in 77% of the IC‑VL patients vs 17% of the 
LV‑HIV patients (P = 0.007). Forty‑two percent of patients fulfilled the criteria for haemophagocytic lymphohistiocy‑
tosis. RDT (rK39‑ICT) serological analysis returned sensitivity and specificity values of 45% and 99%, respectively, and 
ELISA/iIFAT returned 96% and 89%, respectively, with no differences in this respect between patient groups. Fourteen 
(13.0%) patients with VL experienced treatment failure, eight of whom were in the IC‑VL group. Treatment with < 21 
mg/kg (total) liposomal amphotericin B (LAB) was associated with treatment failure in the IC‑VL patients [P = 0.002 
(OR: 14.7; 95% CI: 2.6–83.3)].
Conclusions: IS‑VL was more common than HIV‑VL; the lack of experience in dealing with IS‑VL is a challenge that 
needs to be met. The clinical features of the patients in all groups were similar, although the HIV‑VL patients expe‑
rienced less fever and had lower plasma ferritin concentrations. RDT (rK39‑ICT) analysis returned a good specificity 
value but a much poorer sensitivity value than reported in other scenarios. The patients with HIV‑VL, IS‑VL and IC‑VL 
returned similar serological results. Current guidelines for treatment seem appropriate, but the doses of LAB required 
to treat patients with HIV‑VL and IS‑VL are poorly defined.
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Background
Visceral leishmaniasis (VL) is the most severe clinical 
manifestation of disease caused by Leishmania para-
sites. In June 2009, an outbreak of leishmaniasis caused 
by Leishmania infantum was declared in the southwest 
of the Madrid region (Spain); the focus was an urban 
park in the town of Fuenlabrada. The incidence before 
the outbreak was around 0.2 cases/100,000 inhabitants 
in the above region, rising to 43.5/100,000 in Fuen-
labrada during the outbreak [1]. With more than 700 
cases declared by December 2016 (the date of the last 
official report [1]) the Fuenlabrada outbreak is the larg-
est in Europe to date, and has not yet been declared 
over. Although most people affected during this out-
break have presented with cutaneous leishmaniasis, 
many patients have presented with VL and most of VL 
patients were immunocompetent and of all ages [2].
Large outbreaks involving zoonotic parasites such as 
L. infantum are very uncommon, especially in a Euro-
pean city [3]. The Fuenlabrada outbreak has some pecu-
liarities. For the first time, hares appear to be the main 
reservoir (dogs, the usual reservoir for L. infantum, 
appear to have no role) [4]. Furthermore, it involves 
the ITS-LOMBARDI strain instead of the more com-
mon MON-1 strain; this new, poorly characterized 
strain was isolated from persons with different clinical 
manifestations of the disease during the outbreak [5]. 
The clinical behaviour of the disease in such an unusual 
scenario was therefore unknown. Indeed, we reported 
the appearance of cases of L. infantum-induced local-
ized leishmanial lymphadenopathy (LLL) during the 
outbreak. Completely different to VL, this rare and for-
tunately benign clinical form is not described in clinical 
guidelines [6].
It was in 2010 that the WHO first recommended 
the management of VL to be individualised accord-
ing to the causal species, the region of the world and 
patient immunological status {i.e. immunocompetent 
(IC-VL), co-infected with HIV (HIV-VL) or immu-
nosuppressed (IS-VL) [7]}. These recommendations 
have been maintained in subsequent guidelines, and 
there have been no essential changes to recommenda-
tions on the management of VL in the Mediterranean 
area. However, recommendation levels regarding some 
aspects of diagnosis and treatment are low [3, 8, 9]. For 
instance, there is no certainty regarding the useful-
ness of the rapid diagnostic test (RDT) based on rK39 
since the results reported have been highly variable by 
region [10]. In addition, the validity of serological tests 
for HIV-VL patients in the HAART era is unknown 
[11] and treatment recommendations for L. infantum-
induced IC-VL, HIV-VL and IS-VL are based on small 
series of patients and even individual cases [3, 8, 9]. 
In this scenario of uncertainty, the aim of the present 
work was to describe our clinical experience in the 
management of such patients, with special attention 
paid to their immunological status. To our knowledge, 
this is the first time that personal, epidemiological, ana-
lytical, diagnostic, treatment and outcome variables 
for patients with IC-VL, HIV-VL and IS-VL have been 
compared for the same outbreak.
Methods
Design
This work was designed as a longitudinal observational 
study of a cohort of consecutive adult patients with VL 
treated at the Hospital Universitario de Fuenlabrada 
(HUF) from June 2009 to June 2018. A descriptive analy-
sis was made of their clinical characteristics, the diagnos-
tic methods employed, their treatment and the progress 
of their disease.
Fuenlabrada hospital and the surrounding population
The HUF is the only public reference hospital for the city 
of Fuenlabrada. Located in the southwest of the Madrid 
region (Spain), its 400 beds serve a population of 221,986 
people.
Inclusion and exclusion criteria
All patients had to be at least 14 years of age at the time 
of diagnosis and fulfil the case definition for VL (see 
below). Patients who had received a solid organ trans-
plant were excluded.
Definitions
The case definition of VL was clinical manifestations 
compatible with the condition plus at least one of the 
following [7]: (i) positive parasitological test (optical 
microscopy of bone marrow aspirate, or blood/bone 
marrow PCR); and (ii) positive serological [RDT rK39-
ICT and ELISA/iIFAT (enzyme-linked immunosorbent 
assay/indirect immunofluorescent antibody test)] test 
plus clinical response to treatment.
Patients with IC-VL were defined as those with VL with 
no apparent immunodeficiency, HIV-VL patients were 
defined as patients with VL plus chronic HIV infection, 
and IS-VL patients as those with VL receiving treatment 
with corticosteroids, methotrexate or anti-TNF drugs, 
regardless of the underlying disease.
Delay in diagnosis was described as the days elapsed 
between the patient reporting the onset of symptoms 
and a diagnosis being made. Treatment outcomes were 
described as [3]: (i) initial response: clinical improve-
ment at the end of treatment; (ii) relapse: recurrence 
(meeting VL criteria once again) after initial response; 
(iii) definitive response/cured patient: absence of clinical 
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symptoms 1 year after finishing treatment or re-treat-
ment after relapse; and (iv) failure: lack of initial response 
and/or relapse.
Haemophagocytic lymphohistiocytosis (HLH) was 
deemed present when at least five of the eight diagnos-
tic criteria re-defined in 2004 by the HLH Study Group 
were met [12]. Only six of the eight criteria were evalu-
ated (the absence of NK activity and soluble CD25 could 
not be tested): (i) fever; (ii) splenomegaly; (iii) cytopenia 
(affecting ≥ 2 of 3 lineages in the peripheral blood); (iv) 
hypertriglyceridaemia and/or hypofibrinogenaemia; (v) 
hemophagocytosis in the bone marrow, spleen or lymph 
nodes; and (vi) ferritin ≥ 500 µg/l.
Variables recorded and diagnostic tests performed
Epidemiological variables
The epidemiological variables recorded were age, gender, 
country of origin, ethnicity, delay in diagnosis, comorbid-
ities (diabetes, cirrhosis, neoplasms), HIV and treatment 
with methotrexate, steroids or anti-TNF.
Clinical variables
The clinical variables recorded were symptoms at diagno-
sis: splenomegaly (examined physically or by ultrasonog-
raphy/CT; defined as a spleen > 13 cm in cephalocaudal 
diameter), anaemia (haemoglobin < 12 mg/dl), leucopenia 
(< 4000 leucocytes/mm3), thrombocytopenia (< 150,000 
platelets/mm3), C-reactive protein (CRP), erythrocyte 
sedimentation rate (ESR) and plasma ferritin.
Diagnostic variables and tests
Parasites were visualised by optical microscopy (bone 
marrow aspirate), cultivation (bone marrow aspirate) in 
Novy-MacNeal-Nicolle medium, or PCR-detected (Leish-
mania spp. DNA) in blood and bone marrow aspirate. All 
samples were sent to the National Center of Microbiol-
ogy, ISCIII (Majadahonda, Madrid), for analysis.
Serological examination included immunochromato-
graphic RDT based on antigen rK39-ICT, iIFAT and/or 
ELISA. The RDT (rK39-ICT) test was performed using 
colorimetric dipsticks, employing the SD Leishmania Ab 
kit (Standard Diagnostics, INC., Yongin-si, Gyeonggi-
do, Korea) according to the manufacturer’s instructions. 
These dipsticks detect antibodies against the rK39 anti-
gen. The results are available in less than 1 h. Our hos-
pital laboratory began using this test in April 2011. 
ELISA was used to detect total antibodies against Leish-
mania using the Leishmania ELISA IgG + IgM kit (Vir-
cell Microbiologists, Granada, Spain). This technique is 
considered as reliable as iIFAT and has been available at 
our hospital since April 2011. Before April 2011, samples 
were sent to the Microbiology Department of the Hos-
pital Universitario Severo Ochoa for iIFAT testing using 
the Leishmania Indirect Immunofluorescence Antibody 
Test kit (Vircell Microbiologists, Granada, Spain). Titres 
≥ 1:80 were considered positive.
Treatment and outcome variables
The following treatment and outcome variables were 
recorded: type of treatment, dose, adverse effects (cre-
atinine > 0.5 mg/dl over baseline, chills), initial response, 
relapse, definitive response/cure, failure and death.
Statistical analysis
Qualitative variables were characterized by their absolute 
and relative frequencies. Quantitative variables were ana-
lysed using the Kolmogorov–Smirnov test to determine 
if they fitted a normal distribution. Results are presented 
as the mean ± standard deviation (SD) for normally dis-
tributed variables, and as the medians plus interquartile 
range (IQR) for those that were not.
Results for categorical variables for the different patient 
groups were examined using the Chi-square test; when 
any frequency was < 5, Fisher’s exact test was used. 
Non-categorical variables were compared using either 
Student’s t-test (for parametric variables) or the Kruskal–
Wallis test (for non-parametric variables).
Multivariate logistic regression was performed to 
determine the association of different variables with “fail-
ure” and “relapse”. The regression model included age, 
sex, sub-Saharan origin, delay in diagnosis, plasma ferri-
tin, HLH, adequacy of liposomal amphotericin B (LAB) 
dose, compliance with secondary prophylaxis (patients 
with HIV-VL) and immunological status. Significance 
was set at P < 0.05. All calculations were performed using 
SPSS v.15.0 software for Windows.
Results
Distribution of cases by immunological status and year
Since the beginning of the outbreak, 111 patients have 
met the case definition criteria for VL. Fourteen patients 
clinically suspected of having VL returned positive sero-
logical results (1 by RDT rK39-ICT and 13 by ELISA) 
but did not meet the case definition criteria. Of these 
14 patients, four had autoimmune disease, two were on 
immunosuppressant therapy, and for two a diagnosis of 
Q fever was made.
The 111 confirmed cases of VL were distributed as fol-
lows: 11 (10%) HIV-VL, 16 (14%) IS-VL and 84 (76%) 
IC-VL; Fig.  1 shows their diagnostic distribution by 
year compared to previous VL cases. Five (3.5%) IC-VL 
patients had liver cirrhosis and three (2.1%) had some 
type of active non-haematological malignancy.
Tables 1 and 2 show patient baseline characteristics at 
the time of HIV-VL or IS-VL diagnosis. No cases of liver 
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tumoral disease or congenital immunodeficiency were 
detected (Table 2).
Clinical features
Table 3 and Fig. 2 show the clinical characteristics of the 
patients according to their immunological status.
The majority of affected immigrants came from Equato-
rial Guinea (n = 24) and Nigeria (n = 14), all of whom had 
been living in Spain for over 6 months. No significant dif-
ferences were recorded for this group with respect to the 
mean distance to the focus of the outbreak (mean ± SD 
908 ± 590 vs 955 ± 551 m for the remaining patients; 
ANOVA: F(1, 99) = 0.058, P = 0.810) or body weight before 
the start of treatment (79.5 ± 18.7 vs 75.4 ± 19.5 kg for the 
remaining patients; ANOVA: F(1, 105) = 1.313, P = 0.26).
Overall, 38% of the patients (56% of the IS-VL patients, 
18% of the HIV-VL and 37% of the IC-VL patients) ful-
filled the criteria for HLH (Table  3). Table  4 shows the 
results for the HLH criteria assessed.
Diagnosis
Table 5 shows the results of the diagnostic tests. Before 
the introduction of the RDT (rK39-ICT) test, the median 
delay in diagnosis was 30 days (IQR: 18.5–82.5). After 
the introduction of the test it decreased to a median of 
16 days (IQR: 10–28) (Kruskal–Wallis H-test: χ2 = 5.094, 
df = 1, P = 0.024).
Treatment and outcome
Three patients with IC-VL were not treated, two with 
IC-VL were lost to follow-up, and one died due to 
complications of advanced cirrhosis before starting 
treatment. A total of 108 patients therefore received 
treatment, 104 with liposomal amphotericin B (LAB) 
and four with amphotericin B lipid complex (LABC) 
(doses shown in Table 6). All HIV-VL patients received 
HAART and secondary prophylaxis for VL after their 
VL diagnosis.
An increase in creatinine of ≥ 0.5 mg/dl over baseline 
was observed in 35 patients (32%), but was reversible 
in all cases. Chills were recorded in 10 patients (9%). 
No significant differences in adverse effects were seen 
between the patient groups.
Fig. 1 Distribution of VL patients diagnosed at the Hospital 
Universitario de Fuenlabrada since its opening. Abbreviations: IC‑VL, 
visceral leishmaniasis in immunocompetent patients; HIV‑VL, visceral 
leishmaniasis in patients with HIV; IS‑VL, visceral leishmaniasis in 
immunosuppressed patients (receiving steroids, methotrexate, 
anti‑TNF)
Table 1 Baseline characteristics of the patients with HIV (HIV‑VL) at the time of VL diagnosis
a How the patients became infected by HIV
b Number of RNA viral copies/ml at the moment of VL diagnosis
Abbreviations: PDU, parenteral drug user; MSM, men who have sex with men; Hetero, heterosexual; CD4, number of CD4 cells/mm3 at the moment of VL diagnosis; 
HAART, highly active antiretroviral therapy; HCV, hepatitis C virus; TDF/FTC/EFV, tenofovir/emtricitabine/efavirenz
Sex, age (years) HIV risk  factora Origin Time between HIV and 
VL diagnoses
HCV co‑infection CD4 Viral  loadb HAART 
Male, 48 PDU Spain 27 years HCV 99 348,063 No
Male, 46 PDU Spain 20 years HCV 4 563,499 No
Male, 34 Hetero Peru 3 years No 29 288,439 No
Female, 45 Hetero Eq. Guinea 4 years No 305 < 20 TDF/FTC/EFV
Male, 48 PDU Spain 16 years HCV 46 660,099 No
Male, 37 Hetero Nigeria 3 months No 322 21,511 No
Female, 21 Vertical Eq. Guinea 21 years No 16 60,600 No
Male, 32 Hetero Romania 20 days No 59 143,400 No
Male, 36 Hetero Nigeria 6 days No 4 1,169,645 No
Male, 39 MSM Poland 5 months No 48 149,661 No
Male, 33 MSM Moldova 2 days No 40 1,610,000 No
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All but one patient met the initial response crite-
ria (99%). The median follow-up of all treated patients 
was 316 weeks (IQR: 216–370), with no significant dif-
ferences with respect to immunological status. Four-
teen treatment failures (12.9%) were noted, 13 relapses 
(12%) and one lack of initial response (0.9%) (Table 6). 
Only four of the 14 patients who failed met the criteria 
for HLH (29%). No association was seen between meet-
ing the criteria for HLH and relapse (P = 0.315). Table 7 
shows the detailed characteristics of the eight IC-VL 
patients who relapsed.
Multivariate analysis identified treatment failure and 
relapse to be associated with doses of < 21 mg/kg in 
IC-VL patients (OR: 14.7; 95% CI: 2.6–83.3; P = 0.002) 
and non-compliance with prophylaxis in HIV-VL (OR: 
7.2; 95% CI: 1.5–34.2; P = 0.013).
Discussion
Clinical features
The epidemiological characteristics of patients with VL 
in Fuenlabrada have undergone no substantial changes 
since the outbreak was declared ten years ago [2]. The 
present sample is dominated by males, as is the case for 
most VL case series [13–16], and contains patients of all 
ages (up to 95 years), as might be expected from data for 
epidemic outbreaks in non-endemic areas. In previous 
IC-VL series, male children dominated the sample, both 
in Spain [17] and in Italy [13, 18–20]. These Italian series 
from more than 20 years ago still form the basis of cur-
rent treatment guidelines for VL, including for adults, 
in the Mediterranean area. In the present outbreak, the 
patients with IS-VL were older. A disproportionately high 
number of sub-Saharan immigrants with VL has been 
recorded since the beginning of the outbreak, despite 
the fact that the foreign population makes up only 13% 
of Fuenlabrada’s population [2], perhaps due to genetic 
factors [6]. The present results suggest that they were not 
infected in their countries of origin, and no differences 
were seen between them and the remaining patients in 
terms of the distance they lived from the focus of the 
outbreak.
Fever, splenomegaly and pancytopenia are the main 
clinical criteria of VL [3, 7], and affected > 90% of the 
patients in the present study. For many, cough, headache 
(in 30%), vomiting and abdominal pain were recorded, 
non-specific symptoms that hinder making a differential 
diagnosis. Certainly, thrombocytopenia, splenomegaly 
and non-specific focalizing symptoms can be confused 
with viral syndromes, or malaria in the case of sub-
Saharan patients, or immunosuppressant-induced pan-
cytopenia in the case of IS-VL patients. In areas where 
VL is little expected, diagnosis can become difficult, as 
revealed by the high median diagnostic delay in the first 
years of the outbreak.
Fever and plasma ferritin were the only clinical features 
that were less frequent in patients with HIV-VL. A lower 
Table 2 Characteristics of the immunosuppressed patients (IS‑VL) at the time of VL diagnosis
a  CE doses (prednisone equivalent): low dose, below 5 mg/day; intermediate dose, 5–10 mg/day; high dose, above 30 mg/day
Abbreviations: RA, rheumatoid arthritis; IBD, inflammatory bowel disease; COPD, chronic obstructive pulmonary disorder; UIP, usual interstitial pneumonia; CE, 
corticosteroids; IL-20, monoclonal antibody anti-IL-20
Sex, age (years) Underlying disease Origin Time between starting 
immunosuppression and VL 
diagnosis
Corticosteroids (CE)a Methotrexate Anti‑TNF Others
Female, 68 RA Spain > 1 year CE, low Methotrexate No No
Male, 50 IBD Spain 4 months CE, intermediate No No No
Male, 88 COPD Spain > 1 year CE, high No No No
Male, 64 Psoriatic arthritis Spain > 1 year No Methotrexate No No
Male, 40 UIP Spain > 1 year CE, intermediate No No Azathioprine
Female, 54 RA Spain > 1 year CE, intermediate Methotrexate Etanercept No
Female, 69 RA Cuba 4 months CE, intermediate Methotrexate No No
Male, 54 Psoriatic arthritis Spain Mtx > 1 year, Eta 10 months CE, low Methotrexate Etanercept No
Male, 65 COPD Spain > 1 year CE, high No No No
Female, 44 IBD Spain > 1 year No No Infliximab Azathioprine
Female, 60 RA Spain > 1 year No Methotrexate No IL‑20
Female, 47 IBD Spain 16 months No No Adalimumab No
Female, 44 Psoriasis Spain > 1 year No Methotrexate No No
Male, 72 Giant‑cell arteritis Spain > 1 year CE, high No No No
Male, 33 Tubulo‑interstitial nephritis Nigeria 5 months CE, high No No No
Male, 30 IgA nephropathy Spain > 1 year CE, low No No No
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Table 3 Clinical characteristics according to immunological status
a Time in days from when patient noticed symptoms to diagnosis
b HLH criteria are shown in Table 4
c IgG positive for other infectious diseases: Borrelia burgdorferi 11, Coxiella burnetti 10, Parvovirus 6, Mycoplasma 4, Chlamydophila 4, Rickettsia 4, Syphilis RPR 2
Abbreviations: n, sample size for each group; IC-VL, visceral leishmaniasis in immunocompetent patients; HIV-VL, visceral leishmaniasis in patients with HIV; IS-VL, 
visceral leishmaniasis in immunosuppressed patients (receiving steroids, methotrexate, anti-TNF), SD, standard deviation; IR, interquartile range; n/T, number of 
positives/total number tested; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HLH: haemophagocytic lymphohistiocytosis
*P < 0.05
IC‑VL (n = 84) HIV‑VL (n = 11) IS‑VL (n = 16) Total VL (n = 111) P-value
Male (%) 73 82 56 71 0.297
Age (mean ± SD, years) 44.0 ± 16.5 38.2 ± 8.0 54.8 ± 16.0 45.0 ± 16.9 ANOVA: F(2, 110) = 6.22, P = 0.017*
Immigrants (%) 58 73 13 53 χ2 = 13.22, df = 2, P = 0.001*
Sub‑Saharan origin (%) 54 36 13 46 χ2 = 9.58, df = 2, P = 0.008*
Diabetes (%) 16 9 13 14 0.828
Distance to park (mean ± SD, m) 922 ± 566 928 ± 701 917 ± 544 921 ± 569 0.999
Delay of  diagnosisa (median (IQR), 
days)
18.5 (14–30) 21 (16–60) 24 (10–60) 20 (13–30) 0.640
Fever (%) 98 73 94 95 χ2 = 11.81, df = 2, P = 0.003*
Asthenia (%) 49 46 69 51 0.315
Weight loss (%) 40 36 31 39 0.786
Anorexia (%) 33 36 25 32 0.784
Cough (%) 31 36 31 32 0.836
Cephalea (%) 35 9 19 30 0.113
Vomiting (%) 21 9 0 16 0.056
Abdominal pain (%) 15 18 12 15 0.762
Odynophagia (%) 10 9 6 9 0.906
Diarrhoea (%) 6 18 13 8 0.314
Dyspnoea (%) 7 9 0 6 0.512
Weight (mean ± SD, kg) 78.5 ± 19.1 68.3 ± 18.0 76.4 ± 20.1 77.1 ± 19.2 0.254
Clinical splenomegaly (%) 29 46 31 31 0.537
Radiological splenomegaly, n/T (%) 75/79 (95) 10/11 (91) 13/15 (87) 93 0.472
Spleen size (mean ± SD, cm) 15.7 ± 2.0 15.9 ± 2.1 15.2 ± 2.32 15.7 ± 2.0 0.627
Anaemia (haemoglobin < 12 mg/
dl) (%)
87 82 94 87 0.599
Haemoglobin (mean ± SD, mg/dl) 10.2 ± 1.7 10.9 ± 1.3 9.4 ± 1.5 10.2 ± 1.7 ANOVA: F(2, 106) = 3.24, P = 0.043*
Leukopenia (< 4000/mm3) (%) 90 82 94 90 0.587
Leucocytes (mean ± SD,  mm3) 2715 ± 902 2513 ± 1208 2470 ± 1083 2658 ± 958 0.565
Thrombocytopenia (< 150,000/mm3) 
(%)
93 91 100 94 0.512
Platelets (mean ± SD,  mm3) 93,379 ± 41,771 103,364 ± 38,263 77,875 ± 29,132 92,111 ± 40,077 0.228
CRP (mean ± SD, mg/dl) 12.2 ± 7.3 8.3 ± 6.8 9.2± 6.9 11.3 ± 7.3 0.112
CRP > 10 mg/dl 56 36 38 51 0.225
Ferritin (median (IQR), ng/ml) 2264 (914–6368.5) 712 (469–1098.5) 1854 (1146–5369) 1969 (838–5784) Kruskal‑Wallis H‑test: χ2 = 6.31, 
df = 2, P = 0.043*
Ferritin > 1000 ng/ml, n/T (%) 56/73 (77) 1/6 (17) 11/14 (79) 68/93 (73) χ2 = 11.81, df = 2, P = 0.005*
ESR, n/T (mean ± SD, mm/h) 25/44 (73 ± 32) 3/6 (73 ± 26) 2/11 (60 ± 35) 30/61 (71 ±32) 0.494
ESR > 70 mm/h, n/T (%) 25/44 (57) 3/6 (50) 2/11 (18) 30/61 (49) 0.072
Triglycerides (mean ± SD, mg/dl) 220 ± 81 170 ± 66 203 ± 64 211 ± 78 0.124
HLHb, n (%) 31 (37) 2 (18) 9 (56) 42 (38) 0.129
Auto‑antibody positive, n/T (%) 13/44 (30) 2/4 (50) 3/14 (21) 18/62 (29) 0.535
Serology infectious  diseasesc positives, 
n/T (%)
25/55 (46) 1/6 (17) 5/10 (50) 31/71 (44) 0.366
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proportion of patients with fever has been described in 
transplanted patients with VL [21]. This has been related 
to the incapacity of the humoral immune system to act 
against the parasite. However, the clinical presentation 
of disease was similar across the three patient groups. 
Some atypical forms, such as mucosal leishmaniasis and 
asymptomatic carriers, can be more common in patients 
co-infected with HIV, but in our experience the clinical 
presentation of HIV-VL was similar, in most cases, to 
that of IC-VL [11].
A large number of patients met the criteria for HLH, a 
syndrome associated with very high mortality [12]. How-
ever, no higher mortality nor risk of relapse was seen in 
the present work; indeed, the response to treatment for 
VL was good. In the Fuenlabrada setting, VL needs to be 
ruled out in all cases of HLH given its prognostic impli-
cations [22]. In the IC-VL and IS-VL patients, plasma fer-
ritin was notably elevated; indeed, such concentrations 
are associated with very few diseases and in the present 
context can be taken as a relatively specific sign of VL.
A high percentage (30%) of patients were positive for 
auto-antibodies (commonly found in patients with VL) 
and for antibodies to other infectious agents (especially 
Borrelia and Coxiella) (45%). VL can therefore be initially 
confused with autoimmune disease [23], and certainly the 
cross-reactivity of these auto-antibodies with the histone 
protein of Leishmania [24] has been described. Thus, 
patients with autoimmune disease but without VL may 
Fig. 2 Age distribution of VL patients during the outbreak. 
Abbreviations: IC‑VL, visceral leishmaniasis in immunocompetent 
patients; HIV‑VL, visceral leishmaniasis in patients with HIV; IS‑VL, 
visceral leishmaniasis in immunosuppressed patients (receiving 
steroids, methotrexate, anti‑TNF)
Table 4 HLH criteria assessed
Abbreviations: n, sample size for each group; IC-VL, visceral leishmaniasis in immunocompetent patients; HIV-VL, visceral leishmaniasis in patients with HIV; IS-VL, 
visceral leishmaniasis in immunosuppressed patients (receiving steroids, methotrexate, anti-TNF)
*P < 0.05
IC‑VL (n = 84) HIV‑VL (n = 11) IS‑VL (n = 16) Total (n = 111) P-value
Fever (%) 98 73 94 95 χ2 = 11.81, df = 2, P = 0.003*
Radiological splenomegaly (%) 95 91 87 93 0.472
Cytopenia (at least 2 blood cell lines) (%) 94 91 94 94 0.930
Hypertriglyceridemia (> 265 mg/dl) (%) 23 9 25 22 0.552
Hemophagocytosis in bone marrow (%) 50 22 75 52 χ2 = 6.69, df = 2, P = 0.035*
Ferritin > 500 mg/l (%) 86 78 93 86 0.551
Table 5 Diagnostic test results
Abbreviations: RDT (rK39-ICT), rapid diagnostic test, immunochromatographic test based on rK39 antigen; n, sample size for each group; IC-VL, visceral leishmaniasis 
in immunocompetent patients; HIV-VL, visceral leishmaniasis in patients with HIV; IS-VL, visceral leishmaniasis in immunosuppressed patients (receiving steroids, 
methotrexate, anti-TNF); n/T, number of positives/total number of tests performed
IC‑VL (n = 84) HIV‑VL (n = 11) IS‑VL (n = 16) Total (n = 111) P-value
RDT (rk39‑ICT) (n/T, %) 26/62 (42) 5/10 (50) 7/12 (58) 38/84 (45) 0.550
ELISA/iIFAT (n/T, %) 77/81 (95) 11/11 (100) 16/16 (100) 104/108 (96) 0.500
Optical microscopy (bone marrow) (n/T, %) 32/78 (41) 5/10 (50) 8/16 (50) 45/104 (43) 0.726
Culture (bone marrow) (n/T, %) 6/28 (21) 3/3 (100) 3/6 (43) 12/37 (32) χ2 = 8.64, 
df = 2, 
p =0.013*
PCR (bone marrow) (n/T, %) 67/73 (92) 9/10 (90) 16/16 (100) 92/99 (93) 0.474
PCR (blood) (n/T, %) 21/25 (84) 4/4 (100) 7/8 (88) 32/37 (87) 0.682
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test positive for Leishmania serology in ELISA. Indeed, 
four of the present patients had false positive serology 
results but did not meet the case definition criteria.
Diagnosis
RDT based on rK39 was introduced during the outbreak 
as a first step test in the diagnosis of VL. Combining 
the RDT test with conventional testing is now recom-
mended in the WHO European guidelines 2017 [3], but 
this was not the case in 2010 [7]. Although RDT has been 
reported as a sensitive and specific test (> 90% for both), 
the results returned have been highly variable by region 
[10]. The two studies performed in Europe reported sen-
sitivities of between 52 and 100% [25, 26]. Its reliabil-
ity for detecting L. infantum in Europe is therefore not 
clear. RDT (rK39-ICT) returned positive results for only 
50% of patients with actual VL, although it had a posi-
tive predictive value (PPV) of 99%. Thus, a negative test 
cannot rule out VL, but a positive test for a patient in 
whom VL is clinically suspected is almost confirmatory. 
Conventional iIFAT and ELISA returned positive results 
for 96% of patients with VL, but at least 13 patients had 
false positive results (PPV 89%). This loss of specificity 
is not surprising in the context of an epidemic in which 
there may be many asymptomatic patients exposed to 
Leishmania who return a positive serological test. Thus, 
according to the present results, a patient with suspected 
VL who returned both positive RDT (rK39-ICT) and 
ELISA/iIFAT tests (regardless of the antibody titre) could 
be treated without the need for any additional test, while 
another disease should be sought in a patient returning 
two negative results. The WHO guidelines recommend 
that, where there is disagreement, a parasitological test 
is advisable, but in our experience this disagreement 
always involves a negative RDT (rK39-ICT) and a posi-
tive ELISA/iIFAT test.
No serological differences were detected between 
the IC-VL, IS-VL and HIV-VL patients. Based on older 
series, serological results are usually understood to be 
the least reliable for diagnostic purposes in patients with 
HIV-VL [11]. However, a recent meta-analysis detected 
Table 6 Dose and clinical outcome in patients with VL 
according to their immunological status
a Usual LAB standard dose (see text): IC-VL 18–21 mg/kg; HIV-VL 30–40 mg/kg; 
IS-VL 21–40 mg/kg
b 3 IC-VL patients with solid neoplasms were treated with 21, 30 and 40 mg/dl 
each, with no relapses
c Relapsed and died during retreatment
d This patient was clinically cured after treatment but voluntarily stopped 
secondary prophylaxis and relapsed
e One patient was clinically cured after treatment but voluntarily stopped 
secondary prophylaxis and relapsed
f Lack of initial response, cured after retreatment
Abbreviations: LAB, liposomal B amphotericin; ABLC, amphotericin B lipid 
complex; IC-VL, visceral leishmaniasis in immunocompetent patients; HIV-VL, 
visceral leishmaniasis in patients with HIV; IS-VL, visceral leishmaniasis in 
immunosuppressed patients (receiving steroids, methotrexate, anti-TNF)
LAB  dosea (mg/kg) VL treated (n = 108) Relapses 
(n = 14, 
13.0%)
IC‑VLb 81 8 (9.9%)
15 2 1 (50.0%)
18 5 3 (60.0%)
21 63 LAB + 2 ABCL 3 (4.6%)
30 5 LAB + 1 ABCL 1 (16.7%)c
HIV‑VL 11 3 (27.3%)
21 1 1 (100%)d
30 4 2 (50.0%)e
40 6 0
IS‑VL 16 3 (18.8%)
21 3 LAB + 1 ABCL 1 (25.0%)f
30 4 1 (25.0%)c
40 8 1 (12.5%)
Table 7 Clinical features of IC‑VL patients who relapsed
a Relapses in persons of sub-Saharan origin with IC-VL: 11.9% (5/42) vs 7.9% (3/38), P = 0.414
Abbreviations: LAB, liposomal B amphotericin; ABLC, amphotericin B lipid complex
Sex, age (years) Origin Sub‑Saharana Days to relapse Drug Dose (mg/kg) Retreatment dose (mg/kg) Status 6 months 
after retreatment
Male, 38 Spain No 270 LAB 15 35 Cured
Male, 95 Spain No 30 LAB 18 30 Cured
Male, 15 Spain Yes 60 LAB 18 30 Cured
Female, 37 Eq. Guinea Yes 115 LAB 18 21 Cured
Female, 64 Eq. Guinea Yes 97 ABLC 21 30 (LAB) Cured
Male, 34 Eq. Guinea Yes 165 LAB 21 20 (LAB + miltefosine) Cured
Male, 39 Nigeria Yes 71 LAB 21 40 Cured
Male, 51 Spain No 190 LAB 30 12 (exitus cirrhosis) Exitus
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better results for the most current series [27]. This might 
be explained in that these older series involved patients 
who were infected via the sharing of needles. Only three 
of the present HIV-VL patients acquired HIV via the par-
enteral route, and even in these patients, HIV was diag-
nosed at least 16 years before VL. It is therefore likely 
that all were infected via the normal vector. To examine 
this further, clinical and epidemiological data should be 
included in future studies on the serology of HIV-VL 
patients.
Treatment and outcome
The treatment of choice for L. infantum-induced IC-VL 
is LAB (18–21 mg/kg total), but the recommendation 
level is low [3, 8]: no double-blind randomised stud-
ies comparing different treatment regimens have been 
undertaken, the case series on which this treatment 
choice is based are > 20 years old, and the data extracted 
from them refer largely to Italian children [13, 18, 19, 28]. 
In one of these studies, 15 mg/kg LAB cured 90% of the 
patients [13]. Given the renal toxicity of this drug, two of 
the present IC-VL patients were treated with 15 mg/kg. A 
cure rate of 100% was hoped for, but one patient relapsed. 
In addition, five IC-VL patients were treated with a dose 
of 18 mg/kg, as recommended by current guidelines [7], 
and three of these (60%) relapsed. Thus, an unexpectedly 
high relapse rate was observed with the < 21 mg/kg dose, 
which was in fact the only factor associated with relapse 
in the IC-VL patients. One might hypothesise about the 
virulence of the strain [29] or whether there are higher 
relapse rates among sub-Saharan patients, but the dif-
ferences are not statistically significant. In our routine 
practice we strongly recommend the use of the standard 
regimen approved by the FDA for adults, i.e. 3 mg/kg/day 
on days 1–5, 14 and 21 in adults with IC-VL [8], avoid-
ing other regimens and doses based on results obtained 
in children [13, 20].
Some guidelines recommended that patients with 
IC-VL should be followed up for 6–12 months [7, 8]. 
During the outbreak, two of our patients (25%) relapsed 
after six months; it would therefore seem sensible to 
monitor patients for up to 12 months [3].
Only three patients with active VL died during the 
outbreak: one IS-VL and two IC-VL patients. The latter 
two had severe chronic liver disease and were in a pre-
transplant situation; the main cause of their deaths was 
deemed to be liver disease. However, the patients who 
also had cancer responded well, with no relapses.
Most guidelines recommend a higher dose of LAB (40 
mg/kg) for patients co-infected with Leishmania and 
HIV, but the level of evidence for this is very low [3, 8]. 
A 30 mg/kg dose has also been recommended [7]. These 
recommendations were initially based on two case 
series, one of ten patients [30] and one of five patients 
[31], collated during the pre-HAART era. In both stud-
ies the initial response was good, but the percentage of 
relapses was high since secondary prophylaxis was not 
provided [32]. Although later, non-randomized studies 
that included HAART and secondary prophylaxis with 
LAB endorsed this strategy [33], the dose has not been 
re-evaluated despite some case series studies report-
ing an initial response with 15 mg/kg [34], 22 mg/kg 
[35] and 30 mg/kg [18]. The present HIV-VL patients 
had a good initial response to both the 30 and 40 mg/
kg doses, so these lower doses seem appropriate. With 
current HAART, patients may certainly require less 
than 30 mg/kg, and secondary prophylaxis could likely 
be safely avoided in selected patients [36]. Multicentre 
trials to investigate the treatment of HIV-VL have been 
called for in different reviews [9, 33].
Finally, the IS-VL patients formed a heterogeneous 
group. It has been reported that steroids, methotrexate 
and anti-TNF drugs may favour the appearance of VL 
(these patients are considered immunosuppressed) [9, 
37, 38]. Current recommendations suggest they should 
be managed in a manner similar to IC-VL patients, but 
this is based on evidence provided by individual cases 
[3, 8, 9]. The present IS-VL patients responded similarly 
to doses of 21 and 40 mg/kg LAB, and no factor associ-
ated with the few relapses recorded could be identified. 
More information on the treatment of such patients is 
required.
The main limitation of this work is its observational 
nature. For any conclusions to be drawn regarding the 
diagnostic tests performed or different treatment regi-
mens tried, comparative clinical trials would need to be 
performed. In addition, the data were collected during 
an epidemic outbreak, and the sample excludes chil-
dren and the recipients of solid organ transplants (to 
whose populations the results cannot be extrapolated).
Conclusions
IS-VL was more frequent than HIV-VL; the lack of expe-
rience in dealing with IS-VL is a challenge that needs to 
be met. Given the present setting, it was deemed always 
appropriate to consider VL in the differential diagnosis of 
fever, splenomegaly, pancytopenia and very high plasma 
ferritin. The clinical features of the patients in each group 
were similar, although HIV-VL patients had less fever 
and lower plasma ferritin. RDT (rK39-ICT) was found 
to be highly specific as a diagnostic test, but much less 
sensitive than reported in other scenarios; however, a 
combination of positive RDT and ELISA or iIFAT tests 
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is enough to warrant the start of treatment. The serology 
of HIV-VL, IS-VL and IC-VL patients was similar. Cur-
rent guidelines for treatment seem appropriate, but the 
doses of LAB requited to treat patients with HIV-VL and 
IS-VL are poorly defined; more information is needed. 
The standard regimen of LAB (3 mg/kg/day on days 1–5, 
14 and 21) seems appropriate for the treatment of adults 
with IC-VL, but not lower doses. Developing methods to 
help predict relapse would be very useful.
Abbreviations
VL: visceral leishmaniasis in immunocompetent adults; IC‑VL: visceral leishma‑
niasis in immunocompetent adults; HIV‑VL: visceral leishmaniasis in patients 
with HIV; IS‑VL: visceral leishmaniasis in patients receiving immunosuppres‑
sants; RDT (rK39‑ICT): rapid diagnostic test, immunochromatographic test 
based on rK39 antigen; LAB: liposomal amphotericin B; HAART : highly active 
antirretroviral therapy; HUF: Hospital Universitario de Fuenlabrada; HLH: hae‑
mophagocytic lymphohistiocytosis.
Acknowledgements
The authors thank the patients who participated in this study. This manuscript 
presents results included in the doctoral thesis of LH.
Authors’ contributions
LH, AC and BM collected, analyzed and interpreted IC‑VL patient data, and 
made major contributions to the writing of the manuscript. LM, JG‑M, JJ and 
IG‑A performed the serological tests. EC and JM interpreted patient data and 
made major contributions to the writing of the discussion section. JMR‑G 
designed the study and analyzed and interpreted the overall VL data. JSM 
collected, analyzed and interpreted patient data and made a major contribu‑
tion to the writing of the manuscript. All authors read and approved the final 
manuscript.
Funding
This work received financial support from the Red de Investigación Coopera‑
tiva en Enfermedades Tropicales (RICET) (RD12/0018/0008; RD16/0027/0017) 
(ISCIII) and the FEDER.
Availability of data and materials
Data supporting the conclusions of this article are included within the article. 
The datasets used and/or analyzed during the present study are available from 
the corresponding author upon request.
Ethics approval and consent to participate
All patients consented to participate in the study. The study was approved by 





The authors declare that they have no competing interests.
Author details
1 Área de Infecciosas, Servicio de Medicina Interna, Hospital Universitario de 
Fuenlabrada, Camino del Molino 2, 28942 Fuenlabrada, Madrid, Spain. 2 Uni‑
versidad Rey Juan Carlos, Avda. Atenas s/n, 28922 Alcorcón, Madrid, Spain. 
3 Área de Microbiología, Servicio de Laboratorio Clínico, Hospital Universitario 
de Fuenlabrada, Camino del Molino 2, 28942 Fuenlabrada, Madrid, Spain. 
4 Centro Nacional de Microbiología, WHO Collaborating Centre for Leishma‑
niasis, Majadahonda, Madrid, Spain. 
Received: 20 March 2019   Accepted: 19 July 2019
References
 1. Dirección General de Salud Pública. Leishmaniasis en la Comunidad 
de Madrid, 2015. http://www.madri d.org/bvirt ual/BVCM0 17837 .pdf. 
Accessed 16 Dec 2018.
 2. Arce A, Estirado A, Ordobas M, Sevilla S, García N, Moratilla L, et al. Re‑
emergence of leishmaniasis in Spain: community outbreak in Madrid, 
Spain, 2009 to 2012. Euro Surveill. 2013;18:20546.
 3. WHO/Regional Office for Europe. Manual on case management and sur‑
veillance of the leishmaniases in the WHO European Region. 2017. http://
www.who.int/leish mania sis/resou rces/978‑92‑89052 ‑51‑1/en/. Accessed 
22 Apr 2018.
 4. Molina R, Jiménez MI, Cruz I, Iriso A, Martín‑Martín I, Sevillano O, et al. 
The hare (Lepus granatensis) as potential sylvatic reservoir of Leishmania 
infantum in Spain. Vet Parasitol. 2012;190:268–71.
 5. Chicharro C, Llanes‑Acevedo IP, García E, Nieto J, Moreno J, Cruz I. 
Molecular typing of Leishmania infantum isolates from a leishmaniasis 
outbreak in Madrid, Spain, 2009 to 2012. Euro Surveill. 2013;18:20545.
 6. Horrillo L, San Martín JV, Molina L, Madroñal E, Matía B, Castro A, et al. 
Atypical presentation in adults in the largest community outbreak 
of leishmaniasis in Europe (Fuenlabrada, Spain). Clin Microbiol Infect. 
2015;21:269–73.
 7. WHO Expert Committee on the Control of the Leishmaniases. Control of 
the leishmaniases: report of a meeting of the WHO Expert Committee 
on the Control of Leishmaniases, Geneva, 22–26 March 2010. https ://
apps.who.int/iris/bitst ream/handl e/10665 /44412 /WHO_TRS_949_eng.
pdf;jsess ionid =92DC9 89D36 7A1E7 AD2FA 0A7E8 A56FB 90?seque nce=1. 
Accessed 22 Apr 2018.
 8. Aronson N, Herwaldt BL, Libman M, Pearson R, Lopez‑Velez R, Weina 
P, et al. Diagnosis and treatment of leishmaniasis: clinical practice 
guidelines by the Infectious Diseases Society of America (IDSA) and the 
American Society of Tropical Medicine and Hygiene (ASTMH). Am J Trop 
Med Hyg. 2017;96:24–45.
 9. van Griensven J, Carrillo E, López‑Vélez R, Lynen L, Moreno J. Leish‑
maniasis in immunosuppressed individuals. Clin Microbiol Infect. 
2014;20:286–99.
 10. Boelaert M, Verdonck K, Menten J, Sunyoto T, van Griensven J, Chappuis 
F, et al. Rapid tests for the diagnosis of visceral leishmaniasis in patients 
with suspected disease. Cochrane Database Syst Rev. 2014;6:CD009135.
 11. Alvar J, Aparicio P, Aseffa A, Den Boer M, Cañavate C, Dedet J‑P, et al. The 
relationship between leishmaniasis and AIDS: the second 10 years. Clin 
Microbiol Rev. 2008;21:334–59.
 12. Henter J‑I, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S, et al. 
HLH‑2004: diagnostic and therapeutic guidelines for hemophagocytic 
lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124–31.
 13. Davidson RN, Di Martino L, Gradoni L, Giacchino R, Gaeta GB, Pempinello 
R, et al. Short‑course treatment of visceral leishmaniasis with liposomal 
amphotericin B (AmBisome). Clin Infect Dis. 1996;22:938–43.
 14. Leta S, Dao THT, Mesele F, Alemayehu G. Visceral leishmaniasis in Ethiopia: 
an evolving disease. PLoS Negl Trop Dis. 2014;8:e3131.
 15. Reis LLD, Balieiro AAS, Fonseca FR, Gonçalves MJF. Changes in the epide‑
miology of visceral leishmaniasis in Brazil from 2001 to 2014. Rev Soc Bras 
Med Trop. 2017;50:638–45.
 16. Sinha PK, van Griensven J, Pandey K, Kumar N, Verma N, Mahajan R, et al. 
Liposomal amphotericin B for visceral leishmaniasis in human immuno‑
deficiency virus‑coinfected patients: 2‑year treatment outcomes in Bihar. 
India. Clin Infect Dis. 2011;53:e91–8.
 17. Ramos JM, Clavijo A, Moral L, Gavilan C, Salvador T, González de Dios J. 
Epidemiological and clinical features of visceral leishmaniasis in children 
in Alicante Province, Spain. Paediatr Int Child Health. 2018;38:203–8.
 18. Davidson RN, Di Martino L, Gradoni L, Giacchino R, Russo R, Gaeta GB, 
et al. Liposomal amphotericin B (AmBisome) in Mediterranean visceral 
leishmaniasis: a multi‑centre trial. Q J Med. 1994;87:75–81.
 19. Syriopoulou V, Daikos GL, Theodoridou M, Pavlopoulou I, Manolaki AG, 
Sereti E, et al. Two doses of a lipid formulation of amphotericin B for 
the treatment of Mediterranean visceral leishmaniasis. Clin Infect Dis. 
2003;36:560–6.
 20. Cascio A. A 6 day course of liposomal amphotericin B in the treatment 
of infantile visceral leishmaniasis: the Italian experience. J Antimicrob 
Chemother. 2004;54:217–20.
 21. Antinori S, Cascio A, Parravicini C, Bianchi R, Corbellino M. Leishmaniasis 
among organ transplant recipients. Lancet Infect Dis. 2008;8:191–9.
Page 11 of 11Horrillo et al. Parasites Vectors          (2019) 12:359 
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
 22. Hernández‑Jiménez P, Díaz‑Pedroche C, Laureiro J, Madrid O, Martín E, 
Lumbreras C. Linfohistiocitosis hemofagocítica: análisis de 18 casos. Med 
Clin. 2016;147:495–8.
 23. Ortiz M, Mon C, Herrero JC, Oliet A, Rodríguez I, Ortega O, et al. Glo‑
merulonephritis and cryoglobulinemia: first manifestation of visceral 
leishmaniasis. Clin Nephrol. 2015;83:370–7.
 24. Lakhal S, Benabid M, Sghaier IB, Bettaieb J, Bouratbine A, Galai Y. The 
sera from adult patients with suggestive signs of autoimmune diseases 
present antinuclear autoantibodies that cross‑react with Leishmania 
infantum conserved proteins: crude Leishmania histone and soluble 
Leishmania antigens [corrected]. Immunol Res. 2015;61:154–9.
 25. Brandonisio O, Fumarola L, Maggi P, Cavaliere R, Spinelli R, Pastore G. 
Evaluation of a rapid immunochromatographic test for serodiagnosis of 
visceral leishmaniasis. Eur J Clin Microbiol Infect Dis. 2002;21:461–4.
 26. Varani S, Ortalli M, Attard L, Vanino E, Gaibani P, Vocale C, et al. Serological 
and molecular tools to diagnose visceral leishmaniasis: 2‑years’ experi‑
ence of a single center in Northern Italy. PLoS ONE. 2017;12:e0183699.
 27. Cota GF, de Sousa MR, Demarqui FN, Rabello A. The diagnostic accuracy 
of serologic and molecular methods for detecting visceral leishmaniasis 
in HIV infected patients: meta‑analysis. PLoS Negl Trop Dis. 2012;6:e1665.
 28. di Martino L, Davidson RN, Giacchino R, Scotti S, Raimondi F, Castagnola 
E, et al. Treatment of visceral leishmaniasis in children with liposomal 
amphotericin B. J Pediatr. 1997;131:271–7.
 29. Domínguez‑Bernal G, Jiménez M, Molina R, Ordóñez‑Gutiérrez L, 
Martínez‑Rodrigo A, Mas A, et al. Characterisation of the ex vivo virulence 
of Leishmania infantum isolates from Phlebotomus perniciosus from 
an outbreak of human leishmaniosis in Madrid. Spain. Parasit Vectors. 
2014;7:499.
 30. Russo R, Nigro LC, Minniti S, Montineri A, Gradoni L, Caldeira L, et al. 
Visceral leishmaniasis in HIV infected patients: treatment with high dose 
liposomal amphotericin B (AmBisome). J Infect. 1996;32:133–7.
 31. Laguna F, Torre‑Cisneros J, Moreno V, Villanueva JL, Valencia E. Efficacy 
of intermittent liposomal amphotericin B in the treatment of visceral 
leishmaniasis in patients infected with human immunodeficiency virus. 
Clin Infect Dis. 1995;21:711–2.
 32. Sundar S, Chakravarty J. Liposomal amphotericin B and leishmaniasis: 
dose and response. J Glob Infect Dis. 2010;2:159–66.
 33. Molina I, Falcó V, Crespo M, Riera C, Ribera E, Curran A, et al. Efficacy of 
liposomal amphotericin B for secondary prophylaxis of visceral leishma‑
niasis in HIV‑infected patients. J Antimicrob Chemother. 2007;60:837–42.
 34. Lebrato JC, García ET, Quero JH, Escobar T. Tratamiento de la coinfec‑
ción VIH‑leishmaniasis visceral con un nuevo régimen de anfotericina B 
liposomal (AMB‑L). Med Clin. 2001;116:395.
 35. Torre‑Cisneros J, Villanueva JL, Kindelan JM, Jurado R, Sanchez‑Guijo P. 
Successful treatment of antimony‑resistant visceral leishmaniasis with 
liposomal amphotericin B in patients infected with human immunodefi‑
ciency virus. Clin Infect Dis. 1993;17:625–7.
 36. Castro A, Carrillo E, San Martín JV, Botana L, Molina L, Matía B, et al. 
Lymphoproliferative response after stimulation with soluble Leishmania 
antigen (SLA) as a predictor of visceral leishmaniasis (VL) relapse in HIV+ 
patients. Acta Trop. 2016;164:345–51.
 37. Zanger P, Kötter I, Kremsner PG, Gabrysch S. Tumor necrosis factor alpha 
antagonist drugs and leishmaniasis in Europe. Clin Microbiol Infect. 
2012;18:670–6.
 38. Pagliano P, Ascione T, Di Flumeri G, Boccia G, De Caro F. Visceral leishma‑
niasis in immunocompromised: diagnostic and therapeutic approach 
and evaluation of the recently released IDSA guidelines. Infez Med. 
2016;24:265–71.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub‑
lished maps and institutional affiliations.
